FDAnews
www.fdanews.com/articles/97358-myriad-epicept-expand-clinical-development-for-licensed-cancer-compound

Myriad, EpiCept Expand Clinical Development For Licensed Cancer Compound

August 17, 2007

Myriad announced that it has initiated a third Phase II clinical trial for Azixa (MPC-6827) in patients with non-small cell lung cancer that has spread to the brain.

The trial is designed to assess Azixa’s safety profile and the extent to which it can improve the overall survival of these patients, Myriad and EpiCept said.

Azixa is a vascular disrupting agent licensed by EpiCept to Myriad Genetics as part of an exclusive, worldwide development and commercialization agreement.

Two additional Phase II trials for Azixa are underway in primary brain cancer and melanoma that has spread to the brain, the companies said.

Myriad said it is responsible for the worldwide development and commercialization of Azixa and any drug candidate that is developed from the series of compounds licensed by EpiCept to Myriad in 2003.